- The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07093346.
- What is being tested: Daily Low-methoxy (LM) pectin supplementation (a dietary polysaccharide from citrus peels) to determine whether it reduces systemic inflammation, modifies gut microbiota composition, and improves metabolic parameters in patients with MASLD.
- Patient eligibility overview: The trial includes adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD), representing a common liver condition in the UK population linked to metabolic syndrome and obesity.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is: -How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals…
- : Inclusion criteria for the main study: * Patients with clinical diagnosis of MASLD (formerly termed non-alcoholic fatty liver disease (NAFLD)), having assessment suggesting that liver fat > 5% (e.g. histological evidence or/ and Transient Elastography using Controlled Attenuation Parameter (CAP)- FibroScan™ in the past month and/or liver imaging (such as ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI)). * Participants willing and able to give informed consent for participation in the study. * Participants aged ≥18 years who have a body mass index (BMI) between 18.5 and 39.9 kg/m2 and stable weight (weight gain or loss ≤ 3kg) for the past 3 months. * For diabetic participants: controlled blood glucose levels Haemoglobin A1C (HbA1c)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.